27 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group http://www.zacks.com/stock/news/379812/mercks-keytruda-gets-fda-nod-for-expanded-lung-cancer-group?cid=CS-ZC-FT-379812 Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
5 Must-Buy Stocks Amid Exaggerated Economic Slowdown http://www.zacks.com/stock/news/389800/5-must-buy-stocks-amid-exaggerated-economic-slowdown?cid=CS-ZC-FT-389800 Apr 22, 2019 - The recently released three major economic data of March clearly indicated that the inherent strength of the economy remains intact.
Is a Beat in Store for AbbVie (ABBV) This Earnings Season? http://www.zacks.com/stock/news/390036/is-a-beat-in-store-for-abbvie-abbv-this-earnings-season?cid=CS-ZC-FT-390036 Apr 22, 2019 - Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap http://www.zacks.com/stock/news/390936/the-zacks-analyst-blog-highlights-commscope-ceridian-hcm-cabot-oil-gas-incyte-and-snap?cid=CS-ZC-FT-390936 Apr 23, 2019 - The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store? http://www.zacks.com/stock/news/390180/exact-sciences-exas-to-post-q1-earnings-whats-in-store?cid=CS-ZC-FT-390180 Apr 22, 2019 - During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock? http://www.zacks.com/stock/news/398878/trevena-trvn-to-post-q1-earnings-what-awaits-the-stock?cid=CS-ZC-FT-398878 Apr 24, 2019 - During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.
What's in the Cards for Sarepta (SRPT) This Earnings Season? http://www.zacks.com/stock/news/404867/whats-in-the-cards-for-sarepta-srpt-this-earnings-season?cid=CS-ZC-FT-404867 Apr 29, 2019 - Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.
Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings? http://www.zacks.com/stock/news/405363/is-a-beat-in-the-cards-for-incyte-incy-in-q1-earnings?cid=CS-ZC-FT-405363 Apr 29, 2019 - Incyte (INCY) is slated to report first-quarter results on Apr 30. Investors will primarily focus on Jakafi sales and pipeline updates.
Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y http://www.zacks.com/stock/news/405929/incyte-incy-q1-earnings-revenues-beat-estimates-up-y-y?cid=CS-ZC-FT-405929 Apr 30, 2019 - While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4258062-incyte-corporation-incy-ceo-herve-hoppenot-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare Apr 30, 2019 - Incyte Corporation (NASDAQ:INCY) Q1 2019 Earnings Conference Call April 30, 2019 08:00 AM ET Company Participants Mike Booth - IR Hervé Hoppenot - CEO Barry Flannelly - EVP, General Manager, U.S. Stev

Pages: 123

Page 1>